Published today in Nature Medicine: Peptomyc’s first MYC inhibitor, OMO-103, demonstrates safety and anti-tumor activity in a phase I clinical trial
… Continue reading Published today in Nature Medicine: Peptomyc’s first MYC inhibitor, OMO-103, demonstrates safety and anti-tumor activity in a phase I clinical trial
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
